Xerophthalmia (Neonatal)
What is Xerophthalmia (neonatal)?
Xerophthalmia is a condition characterized by dryness of the conjunctiva and cornea that can lead to ulceration, scarring, and even blindness if left untreated. In newborns, the disease is most often a manifestation of severe vitamin A deficiency (VAD), but it can also result from other systemic or ocular disorders that impair tear production or damage the ocular surface.
Because an infant’s visual system is still developing, even a brief period of ocular surface injury can have long‑term consequences for visual acuity and depth perception. Therefore, early recognition and treatment are crucial.
Common Causes
In the neonatal period (birth to 28 days), xerophthalmia is most frequently linked to nutritional deficiency, but several other conditions can produce a similar dry‑eye picture.
- Severe Vitamin A deficiency – the classic cause; common in low‑income settings with limited vitamin‑A‑rich foods.
- Prematurity – premature infants have immature lacrimal glands and reduced tear secretion.
- Congenital ectodermal dysplasia – a genetic disorder affecting sweat, hair, and tear gland development.
- Congenital lacrimal gland agenesis or hypoplasia – rare developmental anomaly.
- Neonatal infections – especially measles, which can precipitate VAD‑related xerophthalmia, and severe conjunctivitis caused by Chlamydia trachomatis or Neisseria gonorrhoeae.
- Systemic disorders causing chronic malabsorption – e.g., cystic fibrosis, short‑bowel syndrome.
- Use of topical ocular medications that are toxic to the surface – for example, excessive topical antibiotics or steroids.
- Exposure to environmental irritants – smoke, dust, or chemicals in the delivery environment.
- Genetic metabolic diseases – such as cystinosis, which can affect tear production.
- Severe dehydration – especially in low‑birth‑weight infants who are not breast‑fed adequately.
Associated Symptoms
Alongside the hallmark dryness, several other ocular and systemic signs frequently accompany neonatal xerophthalmia:
- Conjunctival follicular hyperplasia or “Bitot’s spots” – foamy, gray‑white patches on the temporal conjunctiva.
- Loss of corneal clarity – cloudiness, haze, or ulceration.
- Excessive photophobia (squinting or tearing in bright light).
- Increased blink rate or persistent eye‑opening difficulty.
- Mucoid or serous discharge from the affected eye(s).
- Signs of systemic vitamin‑A deficiency: respiratory infections, skin keratinization (dry, rough skin), and growth retardation.
- In premature infants, poor weight gain and apnea may coexist.
When to See a Doctor
The newborn eye is delicate; any abnormal finding warrants prompt evaluation. Parents and caregivers should seek medical attention if they notice:
- Visible white or gray patches on the inner surface of the eyelid or conjunctiva.
- Persistent tearing, discharge, or crusting that does not improve with gentle cleaning.
- Redness, swelling, or obvious irritation of the eye.
- Difficulty keeping the eyes open, especially in bright environments.
- Signs of systemic vitamin‑A deficiency (e.g., rough skin, frequent respiratory infections).
- Any sudden change in eye appearance in a preterm or low‑birth‑weight infant.
Early ophthalmic review can prevent progression to corneal ulceration, scarring, and permanent vision loss.
Diagnosis
Diagnosis is a combination of clinical observation, history taking, and targeted investigations.
Clinical Examination
- Fundoscopic and slit‑lamp examination (performed by an ophthalmologist) to assess conjunctival dryness, Bitot’s spots, corneal integrity, and presence of ulceration.
- Tear film assessment – Schirmer test is rarely feasible in newborns but can be approximated by observing tear meniscus.
- Evaluation for other ocular anomalies (e.g., nasolacrimal duct obstruction).
Laboratory Tests
- Serum retinol level – a level < 0.70 µmol/L indicates deficiency (WHO criteria).
- Complete blood count and inflammatory markers if infection is suspected.
- Stool or sweat chloride testing if cystic fibrosis is a differential.
- Genetic testing for ectodermal dysplasia or metabolic disorders when indicated.
Imaging (rarely needed)
- Orbital ultrasound or MRI may be ordered if there is concern for deeper orbital pathology.
Treatment Options
Therapy is aimed at restoring ocular surface moisture, treating the underlying cause, and preventing complications.
Vitamin A Repletion
- High‑dose oral vitamin A is the cornerstone. The WHO recommends 200,000 IU (≈ 60 mg retinol) orally on day 1, repeat on day 2, and a third dose 2 weeks later for infants > 6 months; for neonates, a dose of 50,000 IU is used under medical supervision.
- Breast‑feeding should be encouraged; mothers may also receive vitamin A supplements to enrich breast milk.
Topical Ocular Therapy
- Lubricating eye drops (preservative‑free artificial tears) 1–2 times per hour while awake.
- Antibiotic ointment (e.g., erythromycin) if there is secondary bacterial contamination.
- Topical vitamin A palmitate** (e.g., 0.5%–1% ointment) can be applied in severe cases, but systemic therapy remains primary.
- Use of a protective eye shield at night to prevent ambient drying.
Management of Underlying Conditions
- For premature infants – ensure optimal **humidified incubator settings** and monitor lacrimal gland function.
- For infections – appropriate systemic antibiotics (e.g., azithromycin for chlamydial conjunctivitis) or antiviral therapy if measles is identified.
- Address malabsorption with dietary counseling, pancreatic enzyme replacement (if cystic fibrosis), or treatment of intestinal disease.
Supportive Care
- Maintain a **humidified environment** (40–60% relative humidity) in the neonatal unit.
- Gentle cleaning of the ocular surface with sterile saline and a soft cotton tip.
- Regular follow‑up with a pediatric ophthalmologist to monitor healing and detect early scarring.
Prevention Tips
- Maternal nutrition: Ensure pregnant and lactating women receive adequate vitamin A (≈ 700–770 µg RAE/day) through diet (liver, dairy, orange‑colored fruits and vegetables) or prenatal supplements.
- Exclusive breast‑feeding for the first 6 months provides natural vitamin A and promotes ocular health.
- Vitamin A supplementation programs in high‑risk regions (WHO recommends a single high‑dose supplement for children 6–59 months; newborns of mothers with VAD should also be considered).
- Neonatal screening for prematurity and low birth weight, with early ophthalmic assessment.
- Avoid exposure to irritants (smoke, chemical fumes) in delivery rooms and home environments.
- Prompt treatment of maternal infections (e.g., measles vaccination before pregnancy) to reduce the risk of infectious‑triggered xerophthalmia.
- Educate caregivers on **recognizing early eye changes** and the importance of timely medical review.
Emergency Warning Signs
Immediate medical attention is required if any of the following occur:
- Rapid worsening of eye redness or swelling.
- Development of a white or yellow membrane on the cornea (suggesting ulceration).
- Sudden loss of eye‑opening ability (lagophthalmos) or eyelid drooping.
- Excessive, thick, purulent discharge indicating a serious infection.
- Signs of systemic deterioration: high fever, difficulty breathing, or seizures.
- Any indication that the infant is in severe pain (crying inconsolably when the eye is touched).
These signs may indicate corneal perforation, severe infection, or impending visual loss and constitute a pediatric ophthalmic emergency.
Key Takeaways
Neonatal xerophthalmia is a preventable and treatable cause of childhood blindness when identified early. The condition is most often a marker of severe vitamin A deficiency, but prematurity, genetic disorders, and infections can also play a role. Prompt diagnosis, high‑dose vitamin A therapy, supportive ocular care, and addressing the underlying cause are essential to preserve vision. Caregivers should be vigilant for eye dryness, Bitot’s spots, and any change in ocular appearance, and seek professional evaluation without delay.
References:
- Mayo Clinic. “Vitamin A deficiency.” Accessed July 2026.
- World Health Organization. “Guidelines for the control of vitamin A deficiency.” 2022.
- Cleveland Clinic. “Dry Eye (Keratoconjunctivitis Sicca).” Updated 2024.
- National Institutes of Health, Office of Dietary Supplements. “Vitamin A Fact Sheet.” 2023.
- American Academy of Pediatrics. “Management of Neonatal Eye Disorders.” Pediatrics, 2021.